Skip to main content

Advertisement

Table 1 The baseline characteristics of all selected patients with hepatocellular carcinoma (HCC)

From: Impact of oral anti–hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization

Characteristic Total ( n= 224)   Antiviral treatment group ( n= 80) Non-antiviral treatment group ( n= 144) P value c
Sex (males:females)   209:15   78:2  131:13 0.092
Age (years) a 49.5 (38.5, 58.0)   48.0 (39.5, 56.0) 50.5 (38.0, 59.0) 0.574
WBC (×10 9 /L) 6.66 ± 2.12   6.38 ± 1.85 6.82 ± 2.25 0.286
HBG (g/L) 137.91 ± 20.28   137.90 ± 22.36 137.90 ± 19.10 0.987
PLT (×10 9 /L) 179.91 ± 84.16   170.30 ± 88.10 185.24 ± 81.71 0.076
ALT (U/L) 58.38 ± 40.62   65.28 ± 44.99 54.54 ± 37.60 0.081
AST (U/L) 84.89 ± 62.44   91.17 ± 63.80 81.40 ± 61.62 0.125
ALB (g/L) 40.10 ± 4.40   39.30 ± 4.55 40.54 ± 4.26 0.032
TBIL (μmol/L) 16.44 ± 7.61   17.73 ± 8.49 15.72 ± 6.99 0.059
AFP (ng/mL) a 1301 (50, 38,398)   1436 (53, 37,546) 1210 (50.74, 39,410) 0.820
AFP (<1,000 ng/mL:>1,000 ng/mL)     108:116     39:41    69:75 0.905
PT (s) 12.58 ± 2.08   12.83 ± 2.05 12.44 ± 2.09 0.052
APPT (s) 27.95 ± 3.85   28.22 ± 3.69 27.80 ± 3.94 0.278
HBeAg (positive:negative)       53:171     24:56      29:115 0.096
HBV DNA (log 10 IU/mL) 4.85 ± 1.86   5.50 ± 1.58 4.48 ± 1.92 <0.001
UICC TNM stage (I:II:IIIa:IIIb + IIIc:IV) 46:25:68:63:22   9:14:25:26:6 37:11:43:37:16 0.024
TNM stage (early:advanced)        71:153     23:57    48:96 0.480
Cycles of TACE (one:more than one)   133:91     37:43    96:48 0.003
Resection after TACE (yes:no)        19:205       7:73      12:132 0.915
Local ablation after TACE (yes:no)        49:175     23:57      26:118 0.064
Sorafenib therapy after TACE (yes: no)        12:212        6:74      6:138 0.288
Subsequent therapy b after TACE (yes:no)        67:157     30:50      37:107 0.065
Chemotherapeutic agents
(epirubicin only:>2 agents)
       53:171     18:62      35:109 0.761
  1. aThe values are presented as median followed by interquartile (P25 and P75) in the parentheses. bSubsequent therapy means any treatment after TACE, including resection, local ablation, or sorafenib therapy. cDifferences between the antivirus group and the non-antivirus group. WBC, white blood cells; HBG, hemoglobin; PLT, platelets; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, serum albumin; TBIL, total bilirubin; AFP, α-fetoprotein; PT, prothrombin time; APTT, activated partial thromboplastin time; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; UICC TNM, International Union Against Cancer tumor-node-metastasis; TACE, transcatheter arterial chemoembolization.